Pim Dekker
Pim Dekker first worked for Diabeter in 2014 when still employed by the medical communications agency Excerpta Medica, Amsterdam, The Netherlands. He joined Diabeter as researcher in July 2018. Previous positions include research assistant at Unilever, Colworth, UK and PhD researcher at the Leiden Universtity Medical Center (LUMC), Leiden, The Netherlands.
Selected important publications include:
- Van Beers et al. BMC Endocr Disord. 2025 Mar 31;25(1):88. Evaluating cloudcare, a population health management system, in persons with type 1 diabetes: an observational study.
- Dekker et al. J Diabetes Sci Technol. 2024 Oct 28:19322968241290259. Twelve-Month Real-World Use of an Advanced Hybrid Closed-Loop System Versus Previous Therapy in a Dutch Center For Specialized Type 1 Diabetes Care
- Dekker et al. BMJ Open. 2024 Jun 19;14(6):e082453.Cohort profile: the 'Biomarkers of heterogeneity in type 1 diabetes' study-a national prospective cohort study of clinical and metabolic phenotyping of individuals with long-standing type 1 diabetes in the Netherlands
- Dekker et al. Diabetes Technol Ther. 2023 Apr 13. Prevalence of and reasons for discontinuation of continuous subcutaneous insulin infusion in people with type 1 diabetes: a systematic review
- Dekker et al. J Pediatr Endocrinol Diabetes Metab. 2022;28(1):101-103. Which C-peptide assay do you use? Increasing need for describing C-peptide assay performance
- De Leur et al. Diabet Med. 2022 May;39(5):e14785. How low is really low? Comparison of two C-peptide assays to establish residual C-peptide production in type 1 diabetes
- Van der Heyden et al. Exp Clin Endocrinol Diabetes. 2021 Jul;129(7):510-518. Losing Track of Lipids in Children and Adolescents with Type 1 Diabetes: Towards Individualized Patient Care
A complete bibliography can be found here.
